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We and other investigators have postulated deterioration of essential choroid plexus (CP) functions in some elderly
and especially Alzheimer’s disease patients based on apparent anatomical, histological and pathological changes in
CP. We have termed this putative phenomenon CP failure. By focusing on four essential energy-requiring CP
functions, specifically ascorbic acid (AA) and folate transport from blood into CSF, transthyretin synthesis and
secretion into CSF, and electrolyte/acid–base balance in CSF, we were able to evaluate the hypothesis of CP failure
by reviewing definitive human data. In both healthy elderly and Alzheimer’s disease patients, the CP functions
normally to transport AA and folates actively from blood into CSF, synthesize and secrete transthyretin into CSF,
and maintain CSF acid–base balance and ion concentrations. These human CSF compositional data provide no
support for the notion of CP failure in elderly humans and Alzheimer’s disease patients.
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The human choroid plexus (CP), a locus of the blood-
CSF barrier (BCSFB), is an organ in the cerebral ventri-
cles weighing approximately 2 grams [1]. The CP epithe-
lium secretes most of the CSF and helps to maintain a
stable extracellular environment for brain (homeostasis)
[2]. The CP achieves these ends, in part, by clearing un-
wanted substances from the CSF [3,4] and by pumping
required compounds including certain vitamins [e.g., as-
corbic acid (AA) and methyltetrahydrofolate (folates)],
hormones and peptides from blood into CSF [2,5]. From
CSF, these substances penetrate into brain because there
is a negligible barrier to penetration via diffusion at the
CSF-brain interfaces [2,6]. CP epithelial cells also syn-
thesize peptides and proteins, e.g., transthyretin, for se-
cretion into CSF [7-9].
In order to perform these functions, the human CP
has an estimated blood flow of 4 to 5 ml/min/g and nor-
mally produces CSF at a rate of ~ 0.4 ml/minute, al-
though there is substantial diurnal variation (see below)* Correspondence: Conrad_Johanson@Brown.edu
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distribution, and reproduction in any medium[2]. The anatomical BCSFB to even small molecules like
urea [10] is due to the tight junctions that join the
single-layered CP epithelial cells [2] in the ventricles and
the multi-layered arachnoid membrane cells in the sub-
arachnoid space. Capillaries in CP are “leaky”, unlike the
microvessels in most of the brain where capillary endothelial
cells are joined by tight junctions: the blood–brain barrier
(BBB) [2].
Soon after our work on the vitamin transport systems
in animal CP almost forty years ago, one of us (RS) and
colleagues proposed that the non-stroke related demen-
tias were due to a central vitamin deficiency state sec-
ondary to CP failure–analogous to renal failure [11].
This hypothesis was based on the anatomical and struc-
tural changes in CP of the elderly, and especially, in de-
mented patients [1]. How could such a severely damaged
CP organ perform adequately in Alzheimer’s disease? Sub-
sequently others refined and expanded this failing CP hy-
pothesis [12,13], including considerations for aging animal
models [14,15]. However, we now summarize human data
demonstrating, in both the elderly and Alzheimer’s pa-
tients, that this hypothesis needs reconsideration. It is im-
portant to resolve such hypotheses so that more fruitful
avenues of research can be pursued.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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In order to evaluate CP function in the elderly and
Alzheimer’s disease patients, we focus on four essential
functions of the CP–AA and folate transport from blood
into CSF via the CP, transthyretin synthesis/secretion
into CSF [14], and CSF ion and pH homeostasis [2,16].
If these four diverse CP-CSF functions are maintained in
human elderly and Alzheimer’s patients, since there are
no known alternative compensating mechanisms at the
BCSFB, such data would strongly intimate that the fun-
damental CP transporters are functioning normally. Be-
fore reviewing the human data, a brief overview of these
transport systems and comments on CSF production
will put the human data in better perspective.
AA transport into brain via CP
Hammarstrom, based on elegant autoradiographic studies
of 14C-ascorbate distribution in mice, first proposed that
AA was transported into CSF, and then brain, via the CP
[6,17,18]. We confirmed and extended this hypothesis in
rabbits [6,17,18]. AA does not enter brain directly through
the capillaries of the BBB. In humans, there is also strong
evidence for CNS penetration via CP-CSF rather than
brain capillaries [18]. Subsequent work showed that the
key AA transport system in CP is the sodium-dependent
vitamin C transport system (SVCT2). SVCT2 is present
on the basal (blood) side of the CP epithelium and neu-
rons [19]. In vivo, in mammals including humans, the CP
efficiently pumps AA from the blood flowing through the
CP into CSF with a step-up in concentration of ~ 4 times
[17-19]. In neurons AA is concentrated by another factor
of ~50 by SVCT2 in the neuronal plasma membrane [19].
Thus, the concentration of AA in human plasma, CSF and
brain neurons is ~ 50, 200, and 10,000 μM; and in whole
brain the concentration approaches several mM [19]. The
KT (one-half saturation concentration) for SVCT2 is ~50 μM
[18,19]. The correctness of this model is corroborated by
the phenotype of SVCT2 knock-out (KO) mice and by the
finding of multiple investigators that there is no SVCT2
protein in brain capillaries [19].
For details of the AA system in CP, there are many ex-
cellent reviews [19-21]. Still unknown is how AA exits
the CP into CSF. But what is clear is how this elegant
system maintains AA homeostasis in the central nervous
system [6,18]. At low plasma concentrations, relatively
more AA is pumped into CSF via the CP; at high con-
centrations, relatively less. In guinea pigs (which like
humans cannot synthesize AA), the brain is the last
organ to be depleted of AA in an experimentally-
induced dietary AA deficiency state [6].
Folate transport into CSF via CP
The folate transport system in CP works similarly to the
AA system, actively pumping methyltetrahydrofolate, theprincipal folate in plasma, into CSF. Consequently, the
steady-state concentration of methyltetrahydrofolate in
CSF is ~2-4 times that of plasma [2,19,20]. The CP
mechanism that transports folate from blood into CSF
requires, in sequence, the folate receptor α (FRα) on the
basal side of CP, the proton-coupled folate transporter
(PCFT; SLC 46A1) and probably the reduced folate car-
rier (RFC; SLC 19 A1) at the apical side of CP [19,20].
There is evidently no FRα or PCFT in brain capillaries
[19,20]. Naturally-occurring human KO’s of either FRα
or PCFT lead to central folate deficiency states, very
low CSF folate concentrations and severe neurologi-
cal disease or death, establishing beyond doubt (in
humans) the role of the CP in pumping folates from
blood into CSF. From CSF, folates are transported into
brain [19,20]. However, the exact mechanism(s) by
which folates in CSF are transferred from human CSF
into brain awaits elucidation. One group has postulated
vesicular transport of folates out of mammalian CP
through CSF and into brain [22]. However, in rabbits,
over 70% of the CSF folate transferred from blood into
CSF is present as free methyltetrahydrofolate not bound
in vesicles [23]. We think that non-vesicular CSF folate
transport occurs in humans since otherwise it would
not be possible to measure CSF folate by current
methods were it mainly bound in vesicles. However, the
proportion of vesicular (if any) vs. non-vesicular trans-
port of folate via human CSF remains to be experimen-
tally determined.Transthyretin synthesis and secretion by CP
Transthyretin (TTR) is a protein of 508 amino acids [7].
Although the CSF protein level is < 1% that of plasma,
approximately 10% of CSF protein is TTR [2,7]. Greater
than 90% of the TTR in CSF is synthesized within and
secreted into CSF by the CP [7]. Fasting reduces serum
TTR (synthesized in liver) while the CSF concentration
remains stable [7].Ion transport and acid–base balance in CSF
Another major function of CP epithelial cells is to main-
tain the Na, K and H ion concentrations in CSF [2,9,24].
Choroidal transport proteins, such as the CSF-facing
Na-K pump and the Na-K-Cl cotransporter [25], actively
maintain CSF [K+] close to 2.9 mM (or mEq/L) and [Na+]
about 150 mM. Acid–base transporters in the BCSFB
stabilize CSF pH near 7.3 [9] and [HCO3
-] at about
24 mM. Perturbations in plasma electrolytes are not mir-
rored in CSF due to: i) the diffusion restriction imposed
by the BCSFB tight junctions and, ii) the transporter activ-
ity by CP epithelium that tightly controls ion concentra-
tions in secreted CSF [9,26,27].
Table 1 Mean plasma and CSF AA concentrations, and
ratios of CSF/plasma AA concentrations in Alzheimer’s
patients and controls*
Assessment Control Alzheimer’s
CSF AA (μM) 183 160
(N) (43) (47)
Plasma AA (μM) 68 47
(N) (43) (47)
Ratio of AA, CSF/plasma 3.0 4.0
(N) (43) (47)
*The data are weighted means of three age-and sex-matched, controlled
studies (See Table 3 of Bowman [36] for details.) Number of subjects is
in parentheses.
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Because reduced CSF production could alter solute con-
centrations in CSF, we reviewed the extant data on CSF
formation in the elderly and Alzheimer’s patients. In the
elderly, several studies have measured CSF production
rates compared to younger humans. In seven normal
elderly and seven young adults, May et al. employed the
invasive Masserman technique which involves withdraw-
ing CSF and then waiting for CSF baseline pressure to
be restored [28]. By this indirect approach, May et al.
reported decreased CSF production in the elderly [28].
However, there are several issues with this un-validated,
fluid removal technique in humans (see below). Alterna-
tively and more recently, a small, non-invasive phase-
mapping study by MRI found no difference in CSF
production in the young versus elderly [29]. In an-
other investigation, Nilsson et al. quantified a >2-fold
diurnal variation in human CSF production employing
MRI analysis [30]. Therefore due to variability in meth-
odology and findings, we conclude that the human CSF
production rate as a function of age requires further
examination.
In a study comparing CSF production in 7 patients with
Alzheimer’s disease versus Parkinson’s patients, Silverberg
et al. reported that CSF production was substantially de-
creased in Alzheimer’s patients [31]. However, they used a
modification of the un-validated Masserman technique
withdrawing 3 ml of ventricular CSF. Moreover, the
Alzheimer’s patients were subject to general anesthesia;
the “control” Parkinson’s patients, “conscious sedation.”
Anesthesia has marked effects on CSF pressure and pro-
duction rates [2]. Therefore the CSF dynamics data gener-
ated by the Masserman approach are not definitive. In the
description below on CSF composition in the elderly and
Alzheimer’s patients, we offer indirect evidence that the
CSF production rate in dementia patients is normal or
near normal. This may bear on interpreting CSF solute
concentrations. Even if CSF formation rate remains stable,
however, there might be a slower CSF turnover rate in
aging or dementia if CSF volume is significantly increased
[9]. A reduced CSF turnover rate [15,32,33] could affect
CSF concentration of passively-distributed substances
(such as albumin) between blood and CSF [34], but
awaiting elucidation is how altered turnover rate would
affect (if at all) the level of substances actively distributed
by carrier mechanisms in CP.
AA in CSF and brain of elderly and Alzheimer’s patients
In a superb study using a validated, non-invasive tech-
nique with magnetic resonance spectroscopy (MRS),
Emir et al. showed that in the elderly (mean age 76; N =
22) the AA concentration in occipital cortex was slightly
higher than in young adults (mean age 20; N = 22) [35].This MRS finding is consistent with an ample supply of
AA to neurons from the CP-CSF nexus.
Three age-and sex-matched, controlled studies of CSF
and plasma AA levels in Alzheimer’s patients were de-
scribed in an excellent review by Bowman [36]. The
mean data from all three AA investigations are summa-
rized in Table 1. What is remarkable (Table 1) is that al-
though the CSF AA concentration was 13% lower in the
Alzheimer’s patients, the mean ratio of CSF/plasma AA
was 33% higher. This is expected of such ratios if the CP
active and carrier-mediated transport is functioning nor-
mally; by Michaelis-Menten transport kinetics as the
plasma concentration declines, relatively more AA is
pumped into the ventricles to maintain CSF (and sec-
ondarily brain) homeostasis. As noted in Table 1, the
mean plasma concentration in the Alzheimer’s patients
was 31% lower than in age and sex-matched controls,
presumably due to less AA in their dietary intake. In a
separate uncontrolled study of 32 Alzheimer’s patients,
Bowman et al. found a mean CSF/plasma ratio of 4.0 ±
0.3 (SEM)– confirming the findings summarized in
Table 1 [37]. Collectively, these data provide no support
for abnormal AA transport function in CP of elderly or
Alzheimer’s patients. In fact, they strongly support the
normal ability of CP in Alzheimer’s patients to actively
concentrate AA in CSF.
CSF folate concentration in elderly and Alzheimer’s
patients
In 36 elderly men and women (mean age 73), Serot et al.
found no difference in the mean concentration of CSF
folate versus that in 60 younger adults (mean age 40)
[38]. However, in 36 Alzheimer’s patients, Serot reported
a 17% mean decrease in CSF folate and an 8% mean de-
crease in plasma folate compared with the 36 elderly
controls [38]. Although the CSF concentration of folate
in Alzheimer’s patients was slightly lower than in aged
controls, it was still within the normal range and not
low enough to cause symptoms. Moreover, the CSF fol-
ate concentration in Alzheimer’s patients was still much
Table 3 [Na+], [K+], [HCO3
−], pH and pCO2 in CSF of
normals, controls and Alzheimer’s patients*
Ion** Normal values≠ Controls Alzheimer’s
[Na+] ------ 146 ± 2 (15) 147 ± 2 (15)
[K+] ------ 2.8 ± 0.1 (15) 2.8 ± 0.1 (15)
[HCO3
- ] 22.9 ± 2.3 (35) ------ 23.4 ± 1.3 (15)
pH 7.31 ± 0.03 (35) ------ 7.33 ± 0.03 (15)
pCO2 (mm Hg) 47.9 ± 5.7 (35) ------ 46.9 ± 3.2 (15)
≠Normals = normal adults; controls = age-and sex-matched elderly.
*[Na] and [K] data are compiled from Vitvitsky et al. [40]. Acid–base data are
obtained from Posner et al. [42] (normal values) and Gottfries et al. [41]
(controls and Alzheimer’s patients).
** Ion concentrations are in mEq/L.
≠ All values are means ± SD; N = number of subjects in parentheses.
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equate CP functioning, i.e., maintenance of CSF folate
against an uphill concentration gradient across the
BCSFB. Others [39] have reported normal CSF folate
concentrations in Alzheimer’s patients and showed, as
expected, a negative correlation between the plasma
folate concentration and the ratio of CSF/plasma folate
(P 0.001). This confirms the normal, saturable operation
of the folate transport system in CP in Alzheimer’s dis-
ease [19,20,23].
CSF transthyretin in the elderly and Alzheimer’s patients
In lumbar CSF of patients with a normal level of CSF
protein and less than three cells/ml of CSF, Serot et al.
measured TTR [7]. As per Table 2, Alzheimer’s patients
had a mean 13% decrease in CSF [TTR] vs. elderly con-
trols, but a CSF TTR level comparable to middle-aged
controls and higher than in young subjects. It is risky to
interpret these data too finely, but clearly Alzheimer’s
patients have a CSF TTR concentration within the nor-
mal range. This strongly implies adequate CP secretory
function.
Moreover, Serot et al. also measured CSF albumin in
these subjects [7]. The mean concentrations of CSF
albumin in the middle-aged controls (N = 51), elderly
(N = 41) and Alzheimer’s patients (N = 40) were 0.21,
0.22, and 0.22 g/L, respectively. These similar CSF albu-
min concentration data fit the notion that there is no ap-
preciable loss of integrity of the blood-CSF barrier with
aging and Alzheimer’s disease. This conclusion seems
likely because increased CP permeability in dementia
would presumably have caused an increased concentra-
tion of CSF albumin. Moreover, deductively, there is
probably no substantial decrement in CSF production
since a lower fluid turnover rate would also tend to
increase the CSF albumin concentration. Others have
reported CSF albumin concentration stability in Alzheimer’s
disease [39].
Stability of CSF electrolytes and pH in Alzheimer’s disease
In Alzheimer’s subjects, there is compelling evidence for
unaltered concentrations of CSF [Na+] and [K+] com-
pared to young subjects and age-matched controls [40]
(Table 3). This is in line with the upregulated Na-K-ClTable 2 Transthyretin (TTR) concentration in lumbar CSF*
Group (mean age) Mean TTR (mg/L) ± SD (N) % control
Age-matched controls (76) 20.0 ± 2.5 (41)
Alzheimer’s patients (74) 17.5 ± 2.0 (40) 87
Middle-aged (41) 17.4 ± 2.4 (51) 87
Youth (10) 15.5 ± 1.8 (17) 78
*Data are compiled from Serot et al. [7].cotransporter protein in human CP in Alzheimer’s dis-
ease [9,13]; this apically-located cotransporter, along
with the Na-K exchange pump, has a putative role in
CSF inorganic ion homeostasis by adjusting ion fluxes
across the CSF-facing membrane of choroid epithelium
[25]. Similarly, Alzheimer’s patients had normal CSF
acid–base balance (pH = 7.33) and pCO2 levels [41,42]
(Table 3). Such CSF acid–base stability in the elderly and
Alzheimer’s subjects points to compensatory functioning
of HCO3
- and H+ transporters at the BCSFB. Accord-
ingly, although the information is somewhat limited, the
available evidence (CSF ion composition data from 30
Alzheimer’s patients and 50 control or normal subjects)
strongly suggests that regulatory Na+, K+ and H+/HCO3
-
transport at the BCSFB is maintained in Alzheimer’s dis-
ease [40-42].Discussion and conclusion
The collective observations for CP-CSF function in four
different complex energy-requiring transport and homeo-
static systems (AA and folate transport into CSF via
CP, TTR synthesis/secretion into CSF by CP, and impres-
sive ion and pH stability in CSF) strongly support the
notion that the CP in elderly and Alzheimer’s patients
generally functions well. This is in the face of clear his-
tological, pathological and anatomical modifications in
CP tissue of some elderly and Alzheimer’s disease pa-
tients [1,12,13,31]. Thus, the hypothesis of compromised
CP homeostatic transport failure in some elderly and
Alzheimer’s patients, postulated earlier by us and others
[11-13], is not supported by the CSF compositional evi-
dence reported in this review. Clearly there is more work
to be done such as resolving CSF production rates using
validated techniques taking diurnal variation, anesthesia
and other factors into account. However, the human
CSF data reported herein by us and others substantiate
the maintenance of CP transport and homeostatic func-
tions in the elderly and Alzheimer’s disease.
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